S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
146 Pounds of Graphite Needed for Each EV (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
146 Pounds of Graphite Needed for Each EV (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
146 Pounds of Graphite Needed for Each EV (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
146 Pounds of Graphite Needed for Each EV (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
NASDAQ:CALA

Calithera Biosciences (CALA) Stock Forecast, Price & News

$0.36
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$0.36
$0.36
50-Day Range
$0.02
$0.37
52-Week Range
$0.01
$5.10
Volume
124,810 shs
Average Volume
78,657 shs
Market Capitalization
$1.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Calithera Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
3,511.1% Upside
$13.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.00mentions of Calithera Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars


CALA stock logo

About Calithera Biosciences (NASDAQ:CALA) Stock

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Stock News Headlines

CALA - Calithera Biosciences, Inc.
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Cala Mariolu
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Cala Llombards
Calithera Biosciences to Liquidate >CALA
See More Headlines

CALA Price History

CALA Company Calendar

Last Earnings
11/08/2021
Today
6/07/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
8
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+3,511.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-39,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.75 million
Book Value
($0.40) per share

Miscellaneous

Free Float
4,550,000
Market Cap
$1.75 million
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Dr. Susan M. Molineaux Ph.D. (Age 69)
    Founder, CEO, Pres & Director
    Comp: $625.81k
  • Ms. Stephanie Wong (Age 49)
    CFO & Sec.
    Comp: $752.42k
  • Dr. Christopher J. Molineaux Ph.D. (Age 70)
    Sr. VP of Devel.
  • Mr. Frank Parlati Ph.D. (Age 54)
    Sr. VP of Research
  • Dr. Susan B. Demo Ph.D.
    Sr. VP of R&D Operations
  • Dr. Allison Dillon Ph.D.
    Sr. VP of Commercial & Portfolio Strategy













CALA Stock - Frequently Asked Questions

Should I buy or sell Calithera Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares.
View CALA analyst ratings
or view top-rated stocks.

What is Calithera Biosciences' stock price forecast for 2023?

3 brokers have issued twelve-month price targets for Calithera Biosciences' stock. Their CALA share price forecasts range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.00 in the next year. This suggests a possible upside of 3,511.1% from the stock's current price.
View analysts price targets for CALA
or view top-rated stocks among Wall Street analysts.

How have CALA shares performed in 2023?

Calithera Biosciences' stock was trading at $3.26 at the beginning of the year. Since then, CALA stock has decreased by 89.0% and is now trading at $0.36.
View the best growth stocks for 2023 here
.

When is Calithera Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CALA earnings forecast
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share for the quarter, topping analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. During the same quarter in the prior year, the company posted ($6.40) earnings per share.

When did Calithera Biosciences' stock split?

Calithera Biosciences shares reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How do I buy shares of Calithera Biosciences?

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.36.

How much money does Calithera Biosciences make?

Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $1.75 million and generates $9.75 million in revenue each year. The biotechnology company earns $-39,650,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.

This page (NASDAQ:CALA) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -